Overview

• A July study at St. Louis University Hospital tracked 110 men and found semaglutide and tirzepatide raised the share with healthy testosterone from 53% to 77% after 18 months.
• Case Western Reserve and Taiwanese cohort analyses associated GLP-1 receptor agonists with a 37% lower dementia risk, 19% fewer strokes and 30% reduced all-cause mortality over up to seven years.
• NHS prescriptions for GLP-1 weight-loss injections jumped from 1.4 million in 2023 to 2.7 million in 2024, while more than one million people in the UK obtain them privately.
• Surveys by the Kinsey Institute found nearly half of GLP-1 users experienced changes in libido or sexual performance, indicating variable impacts on reproductive health.
• Researchers and regulators warn that current findings are correlational and urge randomized clinical trials to establish causation, assess rare side effects and confirm long-term safety.